An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
Clinical trial NCT02654132 · COMPLETED
Trial details
- NCT number
- NCT02654132
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-03-18
- Primary completion
- 2018-01-17
- Enrollment
- 117
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.